
doi: 10.1093/ajh/3.4.331
pmid: 2189445
This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy. The ACE inhibitors are assuming a dominant role in our therapeutic armamentarium, in that they are well-tolerated and very effective in the treatment of mild, moderate or severe hypertension.
Humans, Angiotensin-Converting Enzyme Inhibitors, Kidney
Humans, Angiotensin-Converting Enzyme Inhibitors, Kidney
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 25 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
